Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

By M. Smith, F. Mcgovern, A. Zietman, M. Fallon, Douglas Hayden, D. Schoenfeld, P. Kantoff, J. Finkelstein. New England Journal of Medicine, 2001

712 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prostate Cancer (2018, methodology): “Using thresholds of 25% and 15% fPSA, fPSA detected prostate cancer earlier than PSA in 71 and 34% of cases, respectively [54].”
Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, positive): “…bone loss at both the hip and the spine in men with nonmetastatic prostate cancer who received gonadotropin-releasing hormone agonist therapy,89 a single annual dose of IV zoledronic acid was recently demonstrated to lead to increases in both spine and hip BMD (rather than the declines seen…”
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (2002, background): “Smith et al. ( 36 ) observed an 8.5% decrease in trabecular bone mineral density of the lumbar spine after approximately 1 year of leuprolide therapy in men with advanced or recurrent prostate cancer, suggesting that this common hormonal therapy may contribute to such bone loss.”
Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015, background): “[15] 47 Prevents decrease in bone mineral density on ADT Risedronate Choo et al.”